Capital Rx
Highlights
- Two key new drug approvals, including Ekterly® (sebetralstat) for treatment of hereditary angioedema (HAE) in patients at least 12 years of age
- One notable expanded indication: Kerendia® (finerenone) – expanded to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%
- Three generic launches including Xarelto® (rivaroxaban)
- Capital Rx's Updated Drug Recall Report: CLICK HERE to review
Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our July 2025 Monthly Drug Update!
Key New Drug Approvals
Zegfrovy™ (sunvozertinib) tablet
Approval Date: 7/2/2025
Indication: Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in adults
Cost*: TBD
Key Consideration:
• First and only oral treatment approved for NSCLC with EGFR exon 20 insertion mutations
• Received priority review and Breakthrough Therapy Designation by the FDA
• Oral tablet taken once daily with food
Press Release: https://www.dizalpharma.com/news/detail?id=95&search=¤tPage=1
Ekterly® (sebetralstat) tablet
Approval Date: 7/3/2025
Indication: Treatment of acute attacks of hereditary angioedema (HAE) in patients at least 12 years of age
Cost*: ~$8,360 per tablet
Key Consideration:
• First and only oral on-demand treatment for HAE approved by the FDA
• Received Orphan Drug Designation by the FDA
• Recommended dose is 2 tablets at onset of HAE attack; a second dose may be repeated in 3 hours if needed for a maximum of 4 tablets per 24 hours
Press Release: https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr
Notable Expanded Indications
• Kerendia® (finerenone) – expanded to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%
Biosimilar Approvals
Kirsty™ (insulin aspart-xjhz) subcutaneous injection
Approval Date: 7/15/2025
Indication: Improve glycemic control in adults and pediatric patients with diabetes mellitus
Additional Information:
• First and only FDA approved biosimilar to NovoLog® (insulin aspart)
• Will be available as single-use prefilled-pens and multi-use vials
Generic Launches
• Eprontia® (topiramate) solution
• Xarelto® (rivaroxaban) suspension
• Dificid® (fidaxomicin) tablet
Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.
--------
* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support